Ng Hau-Yee, Ma Wei, Lam Wai-Kei J, Lau Chak-Sing, Luk Ho-Ming, Au Lisa W C, Cheng Shirley S W, Chong Josephine S C, Ho Stephanie, Ma Becky M, Pang Shirley Y Y, Chu Annie T W, Chung Brian H Y
Hong Kong Genome Institute, Hong Kong, China.
Department of Chemical Pathology, the Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong, China.
HGG Adv. 2025 Jul 10;6(3):100469. doi: 10.1016/j.xhgg.2025.100469. Epub 2025 Jun 16.
The total burden of rare diseases is significant worldwide, with over 300 million people being affected. Many rare diseases have both well-defined clinical phenotypes and established genetic causes. However, a remarkable proportion of patients with high clinical suspicion of a rare disease remain genetically undiagnosed and stuck in the diagnostic odyssey after having a cascade of conventional genetic tests. One of the major factors contributing to this is that many types of variants are technically intractable to whole-exome sequencing (WES). In this study, the added diagnostic power of whole-genome sequencing (WGS) for patients with clinically suspected rare diseases was assessed by detecting technically challenging variants. 3,169 patients from the Hong Kong Genome Project (HKGP) were reviewed, identifying 322 individuals having high clinical suspicion of a rare disorder with well-established genetic etiology. Notably, 180 patients have performed at least one previous genetic test. Through PCR-free short-read WGS and a comprehensive in-house analytic pipeline, causative variants were found in 138 patients (138 of 322, 42.9%), 30 of which (30 of 138, 21.7%) are attributed to technically challenging variants. These included 6 variants in low-coverage regions with PCR bias, 2 deep intronic variants, 2 repeat expansions, 19 structural variants, and 2 variants in genes with a homologous pseudogene. The study demonstrated the indispensable diagnostic power of WGS in detecting technically challenging variants and the capability to serve as an all-in-one test for patients with high clinical suspicion of rare diseases.
全球范围内,罕见病的总体负担相当大,超过3亿人受到影响。许多罕见病都有明确的临床表型和已确定的遗传病因。然而,相当一部分临床高度怀疑患有罕见病的患者在进行一系列传统基因检测后,仍然无法通过基因检测确诊,陷入诊断困境。造成这种情况的一个主要因素是,许多类型的变异在技术上难以通过全外显子组测序(WES)检测到。在本研究中,通过检测技术上具有挑战性的变异,评估了全基因组测序(WGS)对临床怀疑患有罕见病患者的额外诊断能力。对香港基因组计划(HKGP)的3169名患者进行了评估,确定了322名临床高度怀疑患有罕见病且遗传病因明确的个体。值得注意的是,180名患者此前至少进行过一次基因检测。通过无PCR短读长WGS和全面的内部分析流程,在138名患者(322名中的138名,42.9%)中发现了致病变异,其中30名(138名中的30名,21.7%)归因于技术上具有挑战性的变异。这些变异包括6个存在PCR偏倚的低覆盖区域变异、2个内含子深处变异、2个重复扩增、19个结构变异以及2个位于具有同源假基因的基因中的变异。该研究证明了WGS在检测技术上具有挑战性的变异方面不可或缺的诊断能力,以及作为对临床高度怀疑患有罕见病患者的一站式检测的能力。